Resection of primary lesion for patients with metastatic breast cancer: where are we now?

被引:6
|
作者
Hu, Qiancheng [1 ]
Zhong, Xiaorong [1 ,2 ,3 ]
Liu, Xu [2 ]
Xie, Yuxin [1 ,2 ]
Hu, Kejia [2 ]
He, Ping [1 ,3 ]
Lu, Donghao [1 ,3 ,4 ]
Zheng, Hong [1 ,2 ,3 ]
机构
[1] Sichuan Univ, West China Med Sch, West China Hosp, Dept Med Oncol,Canc Ctr, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Med Sch, West China Hosp,Natl Collaborat Innovat Ctr Bioth, State Key Lab Biotherapy,Lab Tumor Mol Diag, Chengdu 610041, Sichuan, Peoples R China
[3] Sichuan Univ, West China Hosp, Clin Res Ctr Breast, Chengdu 610041, Sichuan, Peoples R China
[4] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
基金
中国国家自然科学基金;
关键词
Breast cancer; distant metastasis; resection of the primary lesion;
D O I
10.21037/cco.2018.05.03
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It is largely unclear that whether or not surgical resection of the primary tumors could confer survival benefit among patients with metastatic breast cancer at initial presentation. We thoroughly reviewed the up-to-date evidence on surgical resection of the primary lesion in metastatic breast cancer, including comparative studies (of particular interest in risk modifiers, the type, and timing of surgical procedures), Chinese and international guidelines, as well as the progress of clinical trials. Partial modified radical mastectomy and breast-conserving surgery are by far the most common choices for patients with metastatic breast cancer. Patients with certain characteristics, for example, younger than 45 years of age or with oligometastasis, might benefit from the surgery. The type and timing of surgical procedures are still in debate according to the guidelines from different countries. Forthcoming evidence from the ongoing clinical trials might help close the knowledge gaps in surgical treatment for patients with metastatic breast cancer and aid the decision-making in clinical practice.
引用
收藏
页数:8
相关论文
共 50 条
  • [11] Prevention of Ovarian Cancer: Where are We Now and Where are We Going?
    Rodriguez, Isabel V.
    Ghezelayagh, Talayeh
    Pennington, Kathryn P.
    Norquist, Barbara M.
    CURRENT ONCOLOGY REPORTS, 2024, 26 (11) : 1355 - 1366
  • [12] Surgical Resection of Primary Tumor for Bone Metastatic Breast Cancer Patients at Initial Presentation
    Kitsuya, Nayu
    Matsuoka, Masatake
    Onodera, Tomohiro
    Yokota, Isao
    Iwasaki, Koji
    Suzuki, Yuki
    Hamasaki, Masanari
    Kondo, Eiji
    Iwasaki, Norimasa
    ANTICANCER RESEARCH, 2024, 44 (04) : 1591 - 1601
  • [13] Capsular Contracture in Breast Implant Surgery: Where Are We Now and Where Are We Going?
    Yara Bachour
    Aesthetic Plastic Surgery, 2021, 45 : 1328 - 1337
  • [14] Capsular Contracture in Breast Implant Surgery: Where Are We Now and Where Are We Going?
    Bachour, Yara
    AESTHETIC PLASTIC SURGERY, 2021, 45 (03) : 1328 - 1337
  • [15] Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
    Colozza, M
    Azambuja, E
    Cardoso, F
    Sotiriou, C
    Larsimont, D
    Piccart, MJ
    ANNALS OF ONCOLOGY, 2005, 16 (11) : 1723 - 1739
  • [16] Clinical versus research approach to breast cancer detection with CAD: Where are we now?
    Brem, Rachel F.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2007, 188 (01) : 234 - 235
  • [17] Accelerated Partial Breast Irradiation (APBI): Where Are We Now?
    Goldberg, Mira
    Whelan, Timothy J.
    CURRENT BREAST CANCER REPORTS, 2020, 12 (04) : 275 - 284
  • [18] Accelerated Partial Breast Irradiation (APBI): Where Are We Now?
    Mira Goldberg
    Timothy J. Whelan
    Current Breast Cancer Reports, 2020, 12 : 275 - 284
  • [19] Regulatory T cells in cancer: where are we now?
    Gallimore, Awen
    Quezada, Sergio A.
    Roychoudhuri, Rahul
    IMMUNOLOGY, 2019, 157 (03) : 187 - 189
  • [20] Breast cancer research: where we are and where we should go
    Liu, ET
    BREAST CANCER RESEARCH, 2000, 2 (02) : 73 - 76